Insulet (PODD)
(Real Time Quote from BATS)
$194.81 USD
+0.43 (0.22%)
Updated Jul 25, 2024 09:50 AM ET
1-Strong Buy of 5 1
D Value C Growth F Momentum D VGM
Insulet (PODD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$232.74 | $270.00 | $185.00 | 19.73% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Insulet comes to $232.74. The forecasts range from a low of $185.00 to a high of $270.00. The average price target represents an increase of 19.73% from the last closing price of $194.38.
Analyst Price Targets (19)
Broker Rating
Insulet currently has an average brokerage recommendation (ABR) of 1.35 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.35 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 16 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 80% and 5% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PODD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 16 | 14 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.35 | 1.35 | 1.35 | 1.35 | 1.39 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Strong Buy | Strong Buy |
5/30/2024 | Atlantic Equities | Issie Kirby | Not Available | Strong Buy |
5/28/2024 | SVB Securities | Michael Kratky | Strong Buy | Strong Buy |
5/13/2024 | Not Identified | Not Identified | Hold | Hold |
5/10/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
5/10/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/10/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
5/10/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Hold | Hold |
5/7/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/23/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Strong Buy |
1/21/2024 | UBS | Danielle Antalffy | Hold | Hold |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
12/21/2023 | Robert W. Baird & Co. | Jeffrey D Johnson | Hold | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.35 |
ABR (Last week) | 1.35 |
# of Recs in ABR | 20 |
Average Target Price | $232.74 |
LT Growth Rate | 17.90% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | 0.56 |